Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy

scientific article published on 14 August 2013

Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.EURURO.2013.08.011
P932PMC publication ID4062940
P698PubMed publication ID24054872
P5875ResearchGate publication ID256928638

P50authorChris PontingQ5107785
Imran AhmadQ41788095
Joanne EdwardsQ42315840
Ian SudberyQ57316959
Prabhakar RajanQ60976609
Andreas HegerQ30503100
Owen J SansomQ37382476
Hing Y LeungQ40453449
P2093author name stringDavid Sims
Ernest Mui
Mark Davis
Ian D Pedley
Janis Fleming
M Eugenia M Villasevil
Rhona M McMenemin
P2860cites workAn integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progressionQ24313269
Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer developmentQ40651903
Activation of β-catenin signaling in androgen receptor-negative prostate cancer cellsQ40834731
Deep sequencing-based expression analysis shows major advances in robustness, resolution and inter-lab portability over five microarray platformsQ41597733
Alterations in beta-catenin expression and localization in prostate cancerQ42813475
Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical stagingQ69737582
Tankyrase inhibition stabilizes axin and antagonizes Wnt signallingQ24316697
The beta-catenin binding protein ICAT modulates androgen receptor activityQ24337124
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancerQ24616117
RNA-seq: an assessment of technical reproducibility and comparison with gene expression arraysQ24655562
The KEGG resource for deciphering the genomeQ27860687
Wnt/β-catenin signalling in prostate cancerQ28269116
Integrins in cancer: biological implications and therapeutic opportunitiesQ29614536
The mutational landscape of lethal castration-resistant prostate cancerQ29614634
The development of androgen-independent prostate cancerQ29615650
WNT signalling pathways as therapeutic targets in cancerQ29615666
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerQ29616218
Increased survival with enzalutamide in prostate cancer after chemotherapyQ29617511
Abiraterone and increased survival in metastatic prostate cancerQ29617512
Identification of novel androgen-regulated pathways and mRNA isoforms through genome-wide exon-specific profiling of the LNCaP transcriptomeQ31043876
Characterization of the small RNA transcriptomes of androgen dependent and independent prostate cancer cell line by deep sequencingQ33770060
A comparison of massively parallel nucleotide sequencing with oligonucleotide microarrays for global transcription profilingQ33881890
Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B.Q34292287
β-catenin is required for prostate development and cooperates with Pten loss to drive invasive carcinomaQ34539930
p68/DdX5 supports β-catenin & RNAP II during androgen receptor mediated transcription in prostate cancerQ34562695
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistanceQ35083279
Recurrent gene fusions in prostate cancerQ37194503
Alternative splicing and biological heterogeneity in prostate cancerQ37573399
Adaptation or selection--mechanisms of castration-resistant prostate cancerQ38068116
Chemical castration and anti-androgens induce differential gene expression in prostate cancer.Q38326753
International variation in prostate cancer incidence and mortality rates.Q38935652
The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man.Q39222325
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancerQ39541646
Docetaxel-resistant prostate cancer cells remain sensitive to S-trityl-L-cysteine-mediated Eg5 inhibitionQ39697788
Relaxin drives Wnt signaling through upregulation of PCDHY in prostate cancerQ39700207
Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancerQ39910338
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectprostate cancerQ181257
RNA sequencingQ2542347
P304page(s)32-39
P577publication date2013-08-14
P1433published inEuropean UrologyQ15763991
P1476titleNext-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy
P478volume66